Corvis (CORV) - Get Correvio Pharma Corp. Report was down 18.3% in early trading as analysts wrangled over Thursday's first-quarter results. Salomon Smith Barney cut its ratings on the stock to outperform from buy, while Credit Suisse First Boston reiterated its strong buy rating. The optical network switch supplier posted a loss of 7 cents a share, meeting the consensus forecast and narrower than the loss of 65 cents in a year ago.

TheStreet Recommends